Here, the 5-year recurrence-free survival (Table 2) for patients with both preoperative tumor markers below the cut-off value was 79% (95% CI 75–83%), 65% (95% CI: CEA: 56–72%; CA19-9: 47–78%) for patients with only the tumor marker CEA or CA19-9 elevated, and 44% (95% CI: 33–56%) for patients with both tumor markers increased. This evidence concerns the gene CEACAM5 and neoplasm.